Charts

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit sol

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resistance to current clinical agents that tar

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “These early clinical data from this multi-center Phase 1 study in patients with metastatic

Gainers Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap ...

Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Dosing Begins in Phase 1 Trial of QN-302 On November 7, 2023, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced that the first three patients have begun dosing in the Phase 1a clinical trial of QN-302. This is a multicenter, open label, dose escalation, and dose expansion trial evaluating the safety,

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024 CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics co

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumo

Gainers Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 ...

Gainers Miromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands ...

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breas

Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1 Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces t

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update IND for QN-302 Cleared; Phase 1 Trial to Initiate in 2H23 On August 1, 2023, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced that the U.S. Food and Drug Administration (FDA) had cleared the Investigation New Drug (IND) application for QN-302, the company’s lead cancer therapeutic development compound. We

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to in

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, toda

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the U.S. Food and Drug

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that it has sold its FastPack® diagnostics business to Chembio Diagnostics, Inc., an American s

Gainers Fresh Tracks Therapeutics (NASDAQ:FRTX) stock rose 35.2% to $0.92 during Friday's pre-market session. The company's market cap ...

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Poster Highlighting Pan-RAS Inhibitor Platform Presented at ASCO On June 5, 2023, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced that a poster featuring the company’s pan-RAS inhibitor program was presented at the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting. The poster highlighted the

Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that a poster featurin

Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Thera

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update IND to be Filed for QN-302 in Mid-2023 Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is continuing work toward the submission of an Investigational New Drug (IND) application for its lead therapeutic program, QN-302. We anticipate an IND being filed for QN-302 in mid-2023. QN-302 is a G-quadruplex (G4)-selective

CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company’s therapeutics pipeline and other corporate developments

Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clini

On Monday, 89 stocks made new 52-week lows. Interesting Facts About Today's 52-Week Lows: Plug Power ...

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. Boxed, Inc. ...

Gainers The Oncology Institute (NASDAQ:TOI) stock moved upwards by 27.6% to $0.86 during Wednesday's regular session. Trading volume ...

Gainers VistaGen Therapeutics (NASDAQ:VTGN) shares rose 37.6% to $0.18 during Wednesday's pre-market session. The market value of their ...

Gainers Virgin Orbit Holdings, Inc. (NASDAQ: VORB) shares rose 81.2% to $0.8032 in pre-market trading. Richard Branson's ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire ...

Gainers Quince Therapeutics (NASDAQ:QNCX) shares increased by 66.3% to $1.4 during Tuesday's pre-market session. The market value of ...

Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 72.2% to $0.79 during Tuesday's after-market session. At the close, ...

During Wednesday's session, 107 stocks hit new 52-week lows. Key Facts About Today's 52-Week ...

Gainers LumiraDx (NASDAQ:LMDX) stock moved upwards by 22.4% to $1.42 during Friday's after-market session. At the close, LumiraDx's ...

During Thursday's session, 97 companies made new 52-week lows. Noteworthy Points From Today's 52-Week ...

On Tuesday, 85 stocks hit new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by ...

Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around ...

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company ...

During Friday's session, 132 stocks hit new 52-week lows. Noteworthy Highlights From Today's 52-Week ...

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on ...

Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX) stock increased by 38.9% to $0.36 during Wednesday's after-market session. AcelRx ...

U.S. stocks traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders ...

Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 49.9% to $0.6 during Thursday's pre-market session. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Qualigen Therapeutics Inc(NASDAQ: QLGN) hasagreed to acquire a majority stakeinNanoSynex Ltd, an ...

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. The post Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Qualigen Therapeutics Inc(NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer ...

Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million ...

Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on ...

Gainers Imperial Petroleum Inc.(NASDAQ: IMPP) rose 45.1% to $1.64 in pre-market trading after gaining around 41% on ...